Pathologic complete response to preoperative immunotherapy in a lung adenocarcinoma patient with bone metastasis: A case report

Anti‐programmed cell death 1 (PD‐1) and its ligand (PD‐L1) has emerged as a novel immunotherapy for non‐small cell lung cancer (NSCLC). However, the proportion of patients who may benefit from immunotherapy is limited and the factors sensitive or resistant to immunotherapy are not completely clear....

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Yong, Li, Yadan, Zhang, Lei, Tong, Guihui, Ou, Zhu'an, Wang, Zhuocai, Zhang, Henghui, Qiao, Guibin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113060/
https://www.ncbi.nlm.nih.gov/pubmed/32077636
http://dx.doi.org/10.1111/1759-7714.13361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113060/
https://www.ncbi.nlm.nih.gov/pubmed/32077636
http://dx.doi.org/10.1111/1759-7714.13361

Ejemplares similares